In recent years, immune checkpoint inhibitors (ICIs), particularly those targeting programmed cell death-1 (PD-1) and its ligand PD-L1 (programmed death-ligand 1), have become a standard treatment and have shown significant efficacy in selected lung cancer patients [3, 4]. The gene discussed is PDCD1; the disease is lung cancer.